Republic Republic Republic
  • Log in
Open account
Oops! We couldn’t find any results...
Can’t find a deal? Try advanced search.
Is something missing? Add your suggestion here.
Primary market Live deals Trading Buy and sell Republic Note Own a piece of Republic's upside
Republic Ventures Opportunities for accredited investors
Republic Capital Multi-stage venture firm
Wallet Manage your digital assets Mobile app Available on iOS or Android Learning center Explore investor resources FAQ Get your questions answered
Capital fundraising Raise on Republic Tokenized assets Design, launch, manage tokenized assets Sharedrops Gift equity as a reward Founder Academy A complete guide to raising funds
Advisory Access veteran web3 advisors Infrastructure Stake your digital assets Tokenization Deploy your assets on-chain
Republic Capital In-house Venture Capital fund Broker dealer Regulated capital services
Republic Republic Republic
Oops! We couldn’t find any results...
Can’t find a deal? Try advanced search.
Is something missing? Add your suggestion here.
  • US

  • Log in
  • Open account
All investors
Primary market Live deals Trading Buy and sell
Republic Note Own a piece of Republic's upside
Accredited only
Republic Ventures Opportunities for accredited investors
Institutional
Republic Capital Multi-stage venture firm
More
Wallet Manage your digital assets Mobile app Available on iOS or Android Learning center Explore investor resources FAQ Get your questions answered
Growth capital solutions
Capital fundraising Raise on Republic Tokenized assets Design, launch, manage tokenized assets Sharedrops Gift equity as a reward Founder Academy A complete guide to raising funds
Web3 services
Advisory Access veteran web3 advisors Infrastructure Stake your digital assets
Tokenization Deploy your assets on-chain
Institutional services
Republic Capital In-house Venture Capital fund
Broker dealer Regulated capital services
Insights

Founders

· June 7, 2018

John Climaco, CNS Pharma

  • Liked
    Like
    0
  • Comment (1)

John Climaco started CNS Pharmaceuticals in search of a simple goal: to cure glioblastoma and other cancers of the brain and central nervous system. To accomplish this, our team is developing anticancer agents that target cancers of the central nervous system. Their lead compound, Berubicin, actually appears to penetrates the blood brain barrier in humans and kill cancer cells.

While drug development is still in the early stages, this compound has the potential to address one of the most intractable problems in cancer. It has been extremely difficult to create effective drugs that can reach the brain and central nervous system.

What inspired you to start your company?

We started the company because of the discovery that our lead compound, Berubicin, could not only kill brain cancer cells in the laboratory but could actually penetrate the blood brain barrier in humans and kill cancer cells.

What's the best career advice you ever received?

Prioritize your health over your career.  It sounds backwards, but I’ve learned the hard way that it’s very difficult to be an effective leader and entrepreneur if you’re not healthy.  Entrepreneurship takes an incredible amount of energy and self-motivation. If you want to succeed, staying healthy is the cornerstone we often forget about when we’re young and take it for granted.

What is your business, and what problem you are solving?

We are in the business of developing anticancer agents that target cancers of the central nervous system. These are some of the most intractable cancer problems because it is extremely difficult to create effective drugs that can reach the brain and central nervous system.

Who is in your core team? What makes your core team a good fit?  

Our core team consists of myself, Dr. Priebe, Dr. Sandra L. Silberman, Dr. Hsu, Dr. Picker, and Matt Lourie our CFO. I believe we make a great fit because we each respect one another’s expertise and role. There is very little overlap among us, enough perhaps that we can sometimes pinch-hit for one another, but not so much that we really ever step on any toes.  A team like this requires direction but not much hand-holding.

How do you see drug development changing in the next five years?

We may see genomic medicine yield a more personalized approach to therapeutics although that promise has been a long time coming. Similarly, immunotherapy holds great promise, but so far the translation from the lab to the clinic has been disappointing.

What makes CNS’s project different?

Our edge is twofold: First, there is our team, which for a project like this is second to none.  Then, there is the IP underlying Berubicin. The compound is completely unique and unlikely to face competition from anything like it.

Why Republic?

We really wanted to democratize the fundraising process and Republic seemed like a platform to do that. I’ve said many times there is nothing inherently or uniquely beneficial in the traditional venture model. All of us had been down that path before and we decided we wanted something different.

What are your interests and passions outside of CNS?

I’m an avid climber and backcountry skier and I love spending time in the mountains with my family.  I’ve climbed all over the world and led several expeditions to the Himalayas. As I write this, I’m headed to Svalbard, a group of islands at 80 degrees north latitude, to sail the coast and ski. Right now, my biggest thrill is being out-skied by my 13-year-old and having my 8-year-old keep up, no matter the terrain.

What's one of your favorite childhood memories?

Running the Colorado River through the Grand Canyon with my dad when I was 10.  Being out of communication for two weeks and camping every night by the rushing river changed my life.

Who is an entrepreneur who inspires you? Why?

Actually my good friend, Rob Tod, the founder of Allagash Brewing in Portland, ME.  After we graduated from Middlebury College, I was with Rob more than 20 years ago when he brewed his first test batch in his kitchen. Today, he is in 48 states and employs over 100 people, having won every major award in the industry along the way.  He has consistently shown me what hard work and determination can do when coupled with passion for an idea.

If you had $1M to invest, where would you put it, besides CNS?

I’d put it into driverless car technology.  To me, there’s no question the last bugs will be worked out and the world will change dramatically.

If you could invite anyone out for a coffee chat, who would it be?

Without a doubt Ernest Shackleton, possibly the greatest polar explorer, and some say overall leader, of all time.  n 1914, he led the Trans-Antarctic Expedition. Early in the trip, his ship, the Endurance, was crushed by ice. He and his crew drifted on sheets of ice for months until they reached Elephant Island.  From there, Shackleton sailed an open lifeboat over 700 miles across the southern ocean to the island of South Georgia. Shackleton crossed glacier-cover and unmapped islands to reach a settlement from which he sailed to Argentina, secured a new ship, and returned to rescue all his men. He not only created the enterprise and secured the financing but, when disaster struck, he pivoted and maintained the morale of his team through one of the worst ordeals in history. I’d love to just ask “how did you do it?”

Share this story

Read next

May Portfolio Update

Republic

May Portfolio Update

New funding rounds, international rollouts, acquisitions, and infrastructure partnerships. Catch up on the latest news from portcos.

Republic launches tokenization of Animoca Brands equity on Solana

Republic

Republic launches tokenization of Animoca Brands equity on Solana

Republic’s tokenization broadens access to Animoca Brands equity for eligible investors worldwide. The initiative leverages Republic’s full-cycle, on-chain infrastructure, seamlessly spanning tokenization, issuance, and secondary market trading.

Republic Joins XDC Network as an Institutional Validator

Digital assets

Republic Joins XDC Network as an Institutional Validator

Strengthening Security for Trade Finance and Real-World Asset Infrastructure

1 comment

Share feedback and comment below. Please note that this section is not monitored by Republic. If you have any questions please reach out to investors@republic.co
The comment you're trying to see no longer exists.
Profile picture of Linda Capson
Linda Capson
7 years ago
Hello dear?
0 Like Reply
Join the discussion
Icon
Verify your identity to join the discussion
To keep discussions authentic and prevent spam,
we ask users to verify their identity.
Verify your identity
Your information is kept secure and will only be used for identity verification.

Get notified about new posts

Not a valid email address
Republic

Giving everyone access to early-stage startup investing

For investors
  • Why invest
  • How it works
  • FAQ
  • Risks
  • Privacy policy
  • Accessibility
  • Cookie Preferences
  • Form CRS
For startups
  • Why raise
  • Learn
  • FAQ
  • Tokenized assets
Company
  • About
  • Insights
  • Events
  • Contact
  • Security
  • We're hiring!
Dollar Refer a startup, get $2,500
Dollar Refer a startup, get $2,500

Invest in the app

Android app iOS app

Invest in the app

Android app iOS app

This site (the "Site") is owned and maintained by OpenDeal Inc., which is not a registered broker-dealer. OpenDeal Inc. does not give investment advice, endorsement, analysis or recommendations with respect to any securities. All securities listed here are being offered by, and all information included on this Site is the responsibility of, the applicable issuer of such securities. The intermediary facilitating the offering will be identified in such offering’s documentation.

By accessing the Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy. Please also see OpenDeal Broker’s Business Continuity Plan and Additional Risk Disclosures. All issuers offering securities under regulation crowdfunding as hosted by OpenDeal Portal LLC are listed on the All Companies Page. The inclusion or exclusion of an issuer on the Platform Page and/or Republic’s Homepage, which includes offerings conducted under regulation crowdfunding as well as other exemptions from registration, is not based upon any endorsement or recommendation by OpenDeal Inc, OpenDeal Portal LLC, or OpenDeal Broker LLC, nor any of their affiliates, officers, directors, agents, and employees. Rather, issuers of securities may, in their sole discretion, opt-out of being listed on the Platform Page and Homepage.

Neither OpenDeal Inc., OpenDeal Portal LLC nor OpenDeal Broker LLC verify information provided by companies on this Site and makes no assurance as to the completeness or accuracy of any such information. Additional information about companies fundraising on the Site can be found by searching the EDGAR database, or the offering documentation located on the Site when the offering does not require an EDGAR filing.

Invest in startups using your credit card
You can invest using your credit card

Made in SF/NYC